An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.

Name: An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.
Creator: Vivli
Published: 2026-03-18 19:35:59
License: 暂无描述

DataCite Commons2026-03-18 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/PR00007890/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

The Sponsor wishes to develop brivaracetam as an anti-epileptic treatment in subjects 16 years and older with epilepsy. This study permits continued access to treatment for subjects who participated in a previous epilepsy study. The study will explore the long-term safety and efficacy of brivaracetam.

提供机构：

Vivli

创建时间：

2022-06-14